NCT03769168CompletedPhase 3
An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
An Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Efficacy, Safety and Tolerability up to 4 Years in Patients With Juvenile Idiopathic Arthritis Subtypes of Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis
Source: ClinicalTrials.gov · Last updated 16 Oct 2025
Brief summary (registry, in English)
Optional open label, roll over extension study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic Arthritis (JIA) subtypes of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA).
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 55 (actual)
- First submitted
- 21 Nov 2018
- Start date
- 7 Jun 2019
- Primary completion date
- 7 Nov 2024
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Psoriatic arthritis
- NCT number
- NCT03769168
- EudraCT number
- 2018-002521-30
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 55
- From 7 Jun 2019 to the primary completion date, 7 Nov 2024
- 21 sites in 9 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with plans for administration of live vaccines during the extension study period were excluded.
- Patients taking any other concomitant biologic immunomodulating agent(s) except secukinumab were excluded.
Other
- Patients who were deemed not to be benefiting from the study treatment based on lack of improvement or worsening of their symptoms were excluded.
Who the study is looking for
- Patients had to have participated in the core study CAIN457F2304 and completed the entire treatment period up to and including Week 104.
- Patients had to be deemed by the investigator to benefit from continued secukinumab therapy.
Age in the registry: 2 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (21)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.